At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 522 enrolled
Drug / intervention
Cethromycin +1 moredrug
Likely dose
Cethromycin 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin 250 mg BID for the Treatment of Community-Acquired Pneumonia in Adults
In Brief
A Phase 3 clinical trial evaluating Cethromycin and Clarithromycin for Pneumonia. Completed, enrolled 522 participants across 13 sites.
Detailed Summary
The purpose of this study is to compare the efficacy and safety of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumonia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedJun 2006
Primary CompletionMay 2007
TodayJul 2026
First PostedJun 13, 2006
Enrollment StartJun 1, 2006
Primary CompletionMay 1, 2007
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 20.1 years ago
Interventions
Cethromycindrug
Cethromycin 300 mg once per day (QD) for 7 days, administered orally
Clarithromycindrug
Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally